Juniper Biologics, based in Singapore, has secured distribution rights for Caris Life Sciences’ solid tumor molecular profiling services in the Middle East and Africa.
This move extends their initial partnership, which covered Southeast Asiam and aims to broaden access to Caris’ advanced cancer profiling technologies across a larger region.
Caris, a precision medicine specialist with a focus on artificial intelligence, offers molecular profiling services which analyze DNA, RNA, and proteins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze